Destiny Pharma targets growth as anti-infection treatments return to prominence

  • Destiny Pharma to present clinical study data at infectious diseases congress
  • Destiny Pharma consultant Professor Dale Gerding updates on recurrent C. difficile infections work

Quick facts: Destiny Pharma PLC


View company profile

Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US and also XF-73 nasal gel, which is reporting results in Q1 2021 from a Phase 2b clinical trial targeting the prevention of post-surgical Staphylococcal hospital infections including MRSA. It is also co-developing SPOR-COV, a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections and has earlier grant funded XF research projects.

10 Jun 2021

(), the biotechnology company focused on the development of novel medicines to prevent life-threatening infections, will present data from its successful Phase 2b clinical study of XF-73 nasal gel at the 2021 ECCMID congress.

An abstract providing analysis and discussion of the late-breaking data arising from the study was accepted for presentation at Europe’s premier antimicrobials congress, the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID).

The congress will be held from July 9 to July 12 of this year.

Read more

07 Jun 2021

() welcomed the outcome of the G7 health ministers’ meeting on 4 June, which concluded with a communique that highlighted the global threat of the “silent pandemic” of antimicrobial resistance (AMR).

The ministers said the G7 should support investment, regulatory and commercial incentives to companies such as Destiny and its peers who are focused on AMR treatments, recognising “the importance of the research and development in new and innovative antimicrobials as well as alternatives to antimicrobials; vaccines, diagnostics and other countermeasures; and the need to take bolder steps to mitigate, minimise and contain the risk of AMR”.

Read more

02 Jun 2021

() chief executive Neil Clark said the group has made significant progress preparing its lead asset, NTCD-M3, for a phase III clinical study, which was on track to go ahead next year.

The microbiome therapeutic is being developed to reduce the recurrence of C.difficile infections () in the gut, the leading cause of hospital-acquired infection in the US.

Read more

02 Jun 2021

Destiny Pharma’s () key consultant and member of the Scientific Advisory Board Professor Dale Gerding provides an update on microbiome therapeutic NTCD-M3 for recurrent C. difficile infections.

The NTCD-M3 programme targets the prevention of the recurrence of clostridium difficile infection and has been developed through the world leading research of Professor Dale Gerding.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is…

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash…


Destiny Pharma (LON:DEST) presenting at the Cenkos Growth & Innovation Forum…

Destiny Pharma (LON:DEST) presenting at the Cenkos Growth & Innovation Forum – Tuesday 8th June 2021

Cenkos Growth & Innovation Forum – Tuesday 8th June 2021

Join Cenkos and Proactive at the Growth & Innovation Forum on Tuesday the 8th June 2021 from 9am onwards. Meet…

3 hours, 9 minutes ago

5 min read


Please enter your comment!
Please enter your name here